Radiation therapy is becoming more responsive to the body’s changing conditions, and artificial intelligence is helping make that shift possible. In adaptive radiotherapy, AI updates the dose and target in real time so treatment can follow the tumor as the patient’s anatomy changes during care.
That approach matters because cancer treatment is rarely static. Tumors can move, organs can shift, and the body itself can change from one session to the next, which makes a fixed radiation plan less reliable than it first appears.
Why a fixed plan is no longer enough
Nearly half of cancer patients worldwide need radiation therapy, so precision has a major impact on care. Conventional radiotherapy works from a plan created at the start, but that plan does not always account for changes in body weight, breathing, or the movement of the bowel and bladder.
Even small shifts can alter where the radiation lands. When that happens, the beam may miss part of the tumor or reach healthy tissue that should have been spared.
How AI changes the treatment flow
Adaptive radiotherapy uses continuously updated imaging to monitor the patient during treatment. Machine learning, advanced imaging, dose optimization, and tumor tracking work together so the radiation plan can be adjusted as the body changes.
This makes the treatment more dynamic than traditional radiation. Instead of relying on one fixed pattern, the system can respond to changes in tumor position and the movement of nearby organs.
Real-time tracking is central to accuracy
The ability to match the beam with natural body motion is one of the most important advantages of the technology. In lung cancer, for example, a tumor may move up and down with breathing, so real-time adjustment becomes especially important.
In older systems, doctors often expanded the treatment area as a precaution. That widened coverage, but it also raised the chance of harming healthy lung tissue and other vital structures.
Adaptive IGRT helps maintain high accuracy while reducing exposure to organs such as the heart, lungs, spinal cord, salivary glands, and bowel structures. That balance is one reason the approach is seen as promising for safer radiation delivery.
Most useful for tumors that move or sit near vital organs
The technology is especially relevant for cancers that are affected by body motion or located close to sensitive tissue. It is considered highly valuable when precision is critical to avoid damaging surrounding organs.
The cancers named as likely to benefit include lung, liver, breast, prostate, and bladder cancer. It is also relevant for head and neck cancer, brain tumors, spinal tumors, and esophageal cancer.
Other groups that may benefit include cancers of the reproductive and digestive systems. Those include cervical, uterine, vulvar, rectal, anal canal, and penile cancers, where nearby sensitive structures make dose accuracy especially important.
Doctors still make the final call
Even with AI in the process, clinical decisions remain with radiation oncologists. The technology supports expert judgment, but it does not replace the need for human validation before treatment is delivered.
Dr. Mathangi J, Senior Consultant and Lead of Radiation Oncology at Gleneagles Cancer Institute Bangalore, is described as combining AI with clinical expertise in techniques such as SRS/SBRT, RapidArc, and image-guided brachytherapy. That combination reflects how machine analysis and medical judgment can work together in cancer care.
As radiation therapy needs remain high worldwide, adaptive AI-guided treatment is being viewed as a more personal and responsive standard. It aims to protect healthy tissue while delivering radiation with greater precision to the tumor itself.
Source: mediaindonesia.com
